同等剂量喹硫平治疗精神分裂症的血药浓度与临床疗效的关系  

The relationship between plasma concentration and clinical efficacy of quetiapine in treatment of schizophrenia with the same dose

作　　者：段迪[1] 凌迎春[1] 周月琴[1] 王玲英[1] 

机构地区：[1]浙江省绍兴市第七人民医院,浙江绍兴312000

出　　处：《药学实践杂志》2012年第3期218-219,共2页Journal of Pharmaceutical Practice

摘　　要：目的研究喹硫平同等剂量治疗精神分裂症时的稳态血药浓度与临床疗效间的关系。方法以固定剂量喹硫平(600 mg/d)治疗148例精神分裂症患者,疗效和不良反应采用简明精神病评定量表(BPRS)和副反应量表(TESS)进行评定,同时测定治疗第2、4、8周的稳态血清药物浓度。结果精神分裂症患者的BPRS减分率与血药浓度之间差异有显著性(P<0.05),血药浓度与不良反应(TESS分值)之间差异无显著性(P>0.05)。结论喹硫平的血药浓度检测有助于确定药物有效浓度及毒性浓度之间的范围,做到用药个体化,指导临床合理用药。Objective To study the relationship between steady-state plasma concentration and clinical efficacy of quetiapine in treatment of schizophrenia with the same dose. Methods 148 schizophrenia patients were treated with quetiapine with the same dose （600 mg/d）. The clinical efficacy and adverse reactions were evaluated with BPRS and TESS respectively, while the plasma concentration of quetiapine was tested at 2nd, 4th and 8th weekend. Results The plasma concentration of quetiapine had significant difference with the reduced rate of BPRS （P 〈 0.05 ）, but had no difference with the scores of TESS. Conclusions The testing of plasma concentration could help to distinguish the effective and toxic concentration of quetiapine in treatment of schizophrenia, which could help doctors to choose rational dose of quetiapine for each patients.

关 键 词：精神分裂症 喹硫平 血药浓度 临床疗效 

分 类 号：R971.41[医药卫生—药品]